Biochem/physiol Actions

(S)-PFI-2 is the negative control probe for (R)-PFI-2 hydrochloride, which is a histone-lysine N-methyltransferase (HKMT) inhibitor selective for SETD7 (SET9). (R)-PFI-2 has 1000-fold selectivity for SETD7 (SET9) over other methyltransferases and other non-epigenetic targets and an IC₅₀ value of 2 nM. (S)-PFI-2 is 500-fold less active. For characterization details of (R)-PFI-2 and (S)-PFI-2, please visit the PFI-2 probe summary on the Structural Genomics Consortium (SGC) website.(R)-PFI-2, the active SETD7 probe, is available from Sigma. To learn more about and purchase (R)-PFI-2, click here.To learn about other SGC chemical probes for epigenetic targets, visit sigma.com/sgc

Features and Benefits

(S)-PFI-2 is an epigenetic chemical probe available through a partnership with the Structural Genomics Consortium (SGC). To learn more and view other SGC epigenetic probes, visit sigma.com/SGC.

This compound is a featured product for Gene Regulation research. Click here to discover more featured Gene Regulation products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.

General description

(S)-PFI-2 is a negative control enantiomer and a biotinylated derivative of (R)-PFI-2, which helps to study the biological activity of SETD7 (SET domain containing (lysine methyltransferase) 7).

Legal Information

Pfizer is a registered trademark of Pfizer, Inc.

Other Notes

This compound was developed by Pfizer for Gene Regulation research. To learn more about Sigma′s partnership with Pfizer and view other authentic, high-quality Pfizer compounds, visit sigma.com/bsm-pfizer.

Packaging

5, 25 mg in glass bottle